The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst like Geulah Livshits from Chardan Capital is likely to instill confidence among investors and could positively influence Tenaya Therapeutics' stock price in the short term. Analyst ratings, especially those that are positive, often lead to increased investor interest and can drive up the stock price.